Results 171 to 180 of about 68,452 (304)

Cryoablation Activates the cGAS–STING‐CXCL10 Axis in Macrophages to Enhance Anti‐Tumor Immunity in NSCLC

open access: yesAdvanced Science, EarlyView.
Tumor dsDNA released by cryoablation is taken up by macrophages, activating the cGAS‐STING signaling pathway. This leads to an expansion of the CXCL10+ macrophage pool and increased secretion of CXCL10, which in turn recruits CXCR3+ T cells from draining lymph nodes into the tumor microenvironment to exert anti‐tumor effects.
Xinxin Zhi   +17 more
wiley   +1 more source

Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges. [PDF]

open access: yesCancer Immunol Immunother
Luo Q   +10 more
europepmc   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu   +4 more
wiley   +1 more source

Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cancer. [PDF]

open access: yesCancer Immunol Immunother
Zhang H   +17 more
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors

open access: yesAdvanced Science, EarlyView.
This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy   +16 more
wiley   +1 more source

One‐Step Glycoengineering of NK Cells With High‐Affinity Siglec Ligands for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study develops an engineered NmCSS enzyme with improved activity for bulky group modified sialic acids, enabling efficient synthesis of structurally diverse sialoside analogs in a single step. Glycan microarray screening identified Siglec high‐affinity ligands, which were incorporated onto natural killer (NK) cells via a one‐pot enzymatic system ...
Shuai Hu   +8 more
wiley   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

open access: yesAdvanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy